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Summary 
To study the role ofCD8 + T  cells in allergic sensitization, we examined the effects of in vivo 
depletion ofCD8 + T  cells prior to sensitization on IgE production, immediate type cutaneous 
hypersensitivity  and  development  of altered  airway  responsiveness.  BALB/c  mice  were 
thymectomized and treated with anti-CD8  antibody resulting in depletion of CD8 + T  cells 
(< 1%) in spleen and lymphoid tissues. In these mice, sensitization to ovalbumin (OVA) via the 
airways still resulted in IgE anti-OVA responses and immediate cutaneous reactions to OVA, 
but the animals were unable to develop airway hyperresponsiveness, eosinophil infiltration of 
the lung parenchyma, or IL-5 production in the local lymph nodes of the airway. Transfer of 
CD8 + T  cells from naive animals during sensitization (on day 8 of the 10-d protocol) fully re- 
stored the ability to develop airway hyperresponsiveness and this was  accompanied by IL-5 
production and  eosinophil accumulation in  the lung.  These data  indicate  a  critical role for 
CD8 + T  cells in the production of IL-5 and the development of altered airway responsiveness 
after antigen sensitization through the airways. 
I 
ncreased airway reactivity (AR) 1 or airway hyperrespon- 
siveness  (AHR) is a general feature of bronchial asthma 
(1).  Whereas AHR may be provoked by many environ- 
mental stimuh, the underlying mechanisms resulting in the 
increased reactivity of the airway smooth muscles are still 
not fully understood. A major contributor appears to be in- 
flammation of the airways, with concomitant increases in 
eosinophil and T cell infiltration of  the airway mucosa (2-5). 
There is increasing evidence for a pivotal role for T lym- 
phocytes in the induction of AHR (6-10). In patients with 
allergic  AHR,  the  production  of allergen-specific  IgE  is 
under the control of T  lymphocytes. IL-4 is released from 
activated T  cells and stimulates B cells to prohferate and to 
undergo isotype switching to produce IgE (11).  A  second 
important cytokine, IL-5, produced by T  lymphocytes and 
other cells, enhances the migration (12), differentiation and 
function (13) of eosinophils and mast cells in humans and an- 
imals  (14,  15),  key cells in the development of AHR.  In- 
IAbbreviations used in this paper: AR, airway activity; AHR, airway  hyper- 
responsiveness; EFS, electrical field stimulation; hpf, high power fields; 
ICH, immediate cutaneous hypersensitivity;  MNC, mononuclear cells; 
OVA, anti-ovalbumin; PBLN, peribronchial  lymph node; PLN, periph- 
eral lymph nodes. 
creased numbers ofeosinophils have been found in biopsies 
(16,  17)  and  broncho-alveolar lavage fluids  (18)  of asth- 
matic patients,  and the  degree of eosinophilic infiltration 
correlates with severity of  the disease (4, 19). CD4 + T lym- 
phocytes from broncho-alveolar lavage fluid (8) or mucosal 
biopsies (20, 21) express elevated levels ofmRNA for IL-4 
and IL-5, and serum IL-5 levels correlate with the numbers 
of eosinophils in peripheral blood (10). 
In contrast to the well-defined role of the CD4 + T  cell 
subset, a distinct role for CD8 + T  cells in the regulation of 
IgE production and development of AHR is less clear. A 
T  suppressor cell dysfunction with impaired concanavalin 
A-induced suppressor cell activity (22)  may be critical for 
the development of allergic diseases and has been described 
in patients with atopic dermatitis, allergic rhinitis and bron- 
chial asthma (23-25). A decrease in the number of periph- 
eral T  suppressor cells was observed in asthma and allergic 
rhinitis and proposed to be causally related to these diseases 
(26,  27).  On the other hand, an increase of CD8 § T  cells 
was observed in the peripheral blood (28) and in broncho- 
alveolar lavage fluid (29) of  asthmatic patients, and CD8 + T 
cell infiltration of the bronchial mucosa after allergic sensi- 
tization has been described in animal models of increased 
AR (30-32). Moreover, CD8 + T  cells, separated from the 
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duce  IL-5  and  enhance  eosinophil  survival  in  vitro  (33). 
Recent studies support the presence  of TH2-1ike CD8 + T 
cells that produce IL-4, IL-5, and IL-10 but not interferon- 
gamma (IFN-~t) or interleukin 2  (IL-2) (34-37). 
To better delineate the role ofCD8 + T  cells in IgE pro- 
duction and in the development of AHR, we studied the 
effects  of in vivo  depletion  of CD8 +  T  cells  in  a  mouse 
model of airway sensitization.  In this model, BALB/c mice 
are  induced  to  develop  elevated  levels  of anti-ovalbumin 
(OVA) IgE (38), allergen-specific immediate cutaneous hy- 
persensitivity  (ICH)  (39)  and  increased  AR  to  electrical 
field stimulation (EFS)  (40) after a 10-d sensitization period 
to aerosolized OVA. These responses also occur after adop- 
tive  transfer  of  sensitized  peribronchial  lymph  node 
(PBLN) cells  (40)  or OVA-specific IgE  + B  cells  (41)  from 
sensitized  animals  to  naive  recipients.  However,  the  in- 
crease in AR also depends on local allergen challenge of the 
airways, suggesting that in addition to a requirement for al- 
lergen-specific  IgE, other factors are necessary for the  de- 
velopment of AHR. 
Here,  we  show that  depletion  of CD8 §  T  cells  before 
sensitization  prevents  the  development  of AHR.  despite 
production  of allergen-specific  IgE  and  development  of 
ICH. The requirement for CD8 + T  cells in the induction 
of AHR  was confirmed in cell transfer experiments;  trans- 
fer of nonprimed CD8 + T  cells restored the ability to de- 
velop  AH1L in  CD8  T  cell-depleted  mice.  The  develop- 
ment  of AHtk  in  sensitized  animals  was  associated  with 
eosinophil infiltration of the lung tissue and increased IL-5 
production  by  PBLN  cells.  The  failure  of CD8  T  celt- 
depleted mice to develop AHR. was associated with the in- 
ability to recruit eosinophils into the lung tissue and a de- 
crease  in  IL-5  production  by  PBLN  cells.  These  data 
suggest a direct, enhancing role of CD8 + T  cells in the de- 
velopment of AHIL through regulation of IL-5 production 
and eosinophil inflammation. 
Materials and Methods 
Animals.  Pathogen-free, female BALB/c mice (Jackson Lab- 
oratories,  Bar Harbor, ME) of 3-12 weeks of age, maintained un- 
der  institutional  approved  guidehnes,  were  used  in  all  experi- 
ments. 
In Vivo CD8 T Cell Depletion.  Mice of 3-4 weeks of age were 
thymectomized and two weeks later were injected i.p.  with 200 
I~l of ascites fluid containing anti-CD8 antibodies  from the clone 
YTS  169  (rat  IgG  anti-mouse  CD8;  American  Type  Culture 
Collection  [ATCC], Rockville,  MD).  Antibody specificity  and 
optimal dilution of the ascites was measured and titrated  in vitro 
and in vivo. Injections were repeated three times at 3-d intervals. 
Control animals received i.p. injections of 0.2 mg rat IgG (Sigma 
Chem.  Co.,  St.  Louis,  MO)  at  the  same  time  points.  Sham 
thymectomy without antibody injection had no effect on any of 
the responses measured. 
Cell Transfer.  CD8 +  T  cells were  positively  selected  from 
spleens  of naive,  nonsensitized BALB/c donor mice using anti- 
CD8  conjugated  magnetic  beads  (Miltenyi  Biotec,  Berglsch- 
Gladbach,  Germany).  The  selected  fraction  contained  >95% 
CD8 + T cells, the depleted fraction contained less than 1% CD8 + 
T  cells as  determined  by FACS analysis.  CD8  T  cell-depleted 
mice were injected with 1 ￿  107 CD8 + T  cells i.v. on day 8 of 
the  10-d sensitization  period. As a control, CD8+-depleted ani- 
mals  received  1  ￿  107  of CD8-depleted  spleen  MNC  (<1% 
CD8 + T cells). 
For in vitro depletion of CD8  § PBLN T  cells before culture, 
anti-CD8 beads were used. 
Sensitization Procedure.  Mice were  exposed to OVA (Sigma) 
as described  previously (40). Briefly,  a solution  of 1% OVA in 
PBS was  delivered by ultrasonic  nebuhzation  for 20  rain  daily 
over a period of 10 consecutive days  (day  1 to  10)  in a closed 
chamber. Control mice were exposed to PBS following the same 
protocol. 
Intradermal Skin Testing.  All mice were tested  for immediate 
cutaneous hypersensitivity  on day 11 as previously described (39). 
Test solutions  were OVA (500 ~g in 1 ml PBS) and PBS. Wheal 
reactions  were  read  after  15-20  min  in  a  blinded  fashion  and 
scored as positive if the diameter in any direction exceeded 3 mm. 
Measurement of  Airway Responsiveness.  Airway  responsiveness 
to electrical field stimulation was determined 2 d after completion 
of the sensitization  protocol as previously described (40). Briefly, 
tracheas were removed and preparations  of~0.5-cm length were 
placed in Krebs-Henseleit solution suspended by triangular  sup- 
ports transducing the force of contractions. Electrical  field stimu- 
lation with an increasing  frequency from 0.5-40 Hz was apphed 
and the contractions measured.  Frequencies  resulting  in 50% of 
the maximal contraction (ESs0) were calculated  from linear  plots 
for each individual  animal  and were compared for the different 
groups. 
Serum Collection.  Venous  blood  was  obtained  from  the  tail 
vein on day 11 and clotted at room temperature. The serum was 
stored after centrifugation (5 re_in, 5,000 rpm) at -20~ 
Determination of Serum Antibody Titers by ELISA.  Serum anti- 
body levels were determined as previously described  (38). Briefly, 
ELISA plates (Dynatech, Chantilly,  VA) were freshly coated with 
OVA (20 I~g in 1 ml NaHCO3 buffer, pH 9.6) or polyclonal goat 
anti-mouse IgE (The Binding Site, Ltd., San Diego, CA; 3 I~g of 
antibodies  in 1 ml buffer)  and incubated overnight at 4~  Plates 
were blocked with 0.2% gelatin  buffer,  pH 8.2, for 2 h at 37~ 
Serum was  diluted  1:10  in gelatin.  Standards  containing OVA- 
specific IgE and lgG1 were generated as described  (39). For total 
immunoglobulins, commercial standards were used (Pharmingen, 
San Diego, CA). ELISA data were analyzed with the Microplate 
Manager software  for the Macintosh computer (Bio-l~ad Labs., 
Richmond). 
Cell Preparation.  Spleens, peripheral  lymph nodes (PLN) (ax- 
illary, brachial,  cervical, inguinal,  para-aortal,  and intestinal lymph 
nodes)  and PBLN were removed and placed in PBS.  Tissue was 
dispersed  into  single  cell  suspensions  and  mononuclear  cells 
(MNC)  were purified by Ficoll-Hypaque gradient centifugation 
(Lymphocyte Separation  Medium;  Organon Teknika,  Durham, 
NC). Cells were washed,  counted and resuspended  to a final con- 
centration of 4 ￿  106 cells per ml in RPMI 1640 (GIBCO BR.L, 
Gaithersburg,  MD) tissue culture medium, containing heat-inac- 
tivated fetal calf serum (FCS  10%; Hyclone, Logan, UT), L-glu- 
tamine (2 mM), sodium pyruvate (1 mM), 2-mercaptoethanol (5 
mM), Hepes buffer (15 mM), penicillin  (100 U/ml), and strepto- 
mycin (100 ~g/ml) (all from GIBCO BRL). 
FACS Analysis.  Spleen MNC and PLN cells from one ani- 
mal in each experimental group were analyzed at day 1 before be- 
ginning the sensitization  protocol; spleen MNC and PBLN were 
analyzed  on day 12 after completion of the sensitization  period. 
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in staining buffer (PBS,  2% FCS, 0.2% sodium azide) with anti- 
CD4 (FITC-R_M4-4; PharMingen, San Diego, CA) or anti-CD8 
(biotin-53.6.7; Pharmingen) antibodies at 4~  Stained cells were 
analyzed using  an  Epics  cytofluorograph  (Coulter  Electronics, 
Hialeah, FL). Fluorescence intensity was compared with negative 
controls and cells incubated with phycoerythrin-coupled strepta- 
vidin alone. 
Histology.  Lung tissue was removed and fixed in 4% paraform- 
aldehyde. 5-~m-thick sections were cut around the main bron- 
chus in a standardized way for all lungs. Eosinophils were stained 
in a combined method using astra blue and vital new red as de- 
scribed (42).  Numbers  of eosinophils were  counted in a  blind 
fashion under light microscopy using 400￿  magnification. A mini- 
mum of 10 high power fields (hp0 were examined and the results 
are expressed as mean +  SD of numbers of eosinophils per hps 
Cytokine Production.  Spleen  MNC  and  PBLN  cells  were 
plated at 4 ￿  106 cells/ml in 96-well round-bottom tissue culture 
plates and  incubated with  PMA  (10  nM)  and  ionomycin  (0.5 
p.M) for 48 h at 37~  Cell-free supematants were harvested and 
cytokine production measured  using  a  mouse  IL-5  ELISA kit 
(Endogen,  Cambridge, MA).  Serum levels of IL-5 were  deter- 
mined similarly. The limits of detection of IL-5 in this kit were 2 
ng/ml. 
Cytoplasmic Staining of Cytokine Protein.  Spleen  MNC  and 
PBLN  cells were prepared for cytoplasmic staining of cytokine 
protein as described (43).  Briefly, cells were stimulated for 4  h 
with PDB  (10  ng/ml)  and ionomycin (0,5  I~M), permeabilized 
with  saponin  (Sigma,  0.1%  in  HBSS),  blocked with  goat  and 
donkey Ig, and then stained with biotinylated anti-IL-5 or anti- 
IFN-~/  antibodies  (PharMingen),  followed  by  PE-conjugated 
streptavidin. In a  second step,  FITC-conjugated anti-CD4  and 
anti-CD8 antibodies (PharMingen) were added and the frequen- 
cies analyzed using an Epics cytofluorograph (Coulter Electron- 
ics).  Fluorescence  intensity  was  compared  to  isotype  controls 
matching the anti-cytokine antibodies or non-stimulated cells. 
Statistical Analysis.  Results  of antibody  and  cytokine  levels 
are expressed as the mean +  SD. The results of the in vitro assess- 
ment of airway responsiveness are reported as the mean -+ SEM. 
The Tukey-Kramer I--ISD  test was used for multiple comparisons 
of the different groups; levels of differences between the individ- 
ual  groups  were  determined by  Student's  two-tailed unpaired 
t test with a P value of <0.05 for significance. 
Results 
Depletion of CD8  + T  Cells In  Vivo 
The aim of these experiments was to investigate the ef- 
fects ofCD8  T  cell depletion before airway sensitization to 
OVA  on  IgE  production,  cutaneous  reactivity and  AR. 
The  status of depletion was  determined by FACS analysis 
of spleen  MNC  and  PLN  cells before  sensitization.  The 
PLN  from  nonsensitized control animals  contained  64  + 
2.9% CD4 +  and 11.3  +  2.2% CD8 + T  cells (Fig. 1).  Fol- 
lowing thymectomy  and  injection of anti-CD8  antibody, 
the PLN contained less than  1% CD8 + T  cells. Similar re- 
sults were  observed for spleen MNC.  After depletion, the 
frequency of CD8 +  T  cells decreased from 7.5  +  1.2% to 
0.9 +-_ 0.3%, whereas CD4 + T  cells remained at similar lev- 
els (35  +  2.5% before vs. 33.2 +- 2.9% after aepletion) (Fig. 
T cell distribution of spleen MNC and PLN 







Figure  1. 
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Thymectomy  and  anti-CD8  antibody  treatment  deplete 
CD8 + T cells. Mice of 3-4 wk of age were thymectomized. 10 d later, 
2001~1 of  mouse ascites containing anti-CD8 antibodies were injected i.p. 
Injections were repeated three times. Control animals received i.p. injec- 
tions of 0.2 mg rat IgG at the same time points. FACS  |  staining of PLN 
cells and spleen MNC for CD4 + and CD8 + T cells was performed on day 
1 of the sensitization  protocol to OVA. Expressed are the frequencies as a 
percent of total MNC for the two T cell subsets of control (n =  20) and 
depleted animals (n =  16) from four independent experiments *P <0.001 
compared to nondepleted controls. 
1). The slight decrease in the number of CD4 + T  cells fol- 
lowing the  depletion protocol is explainable by depletion 
of CD4+/CD8 + double-positive T  cells. The total number 
of spleen MNC  per mouse was reduced by 10.5% from 38 
+  4  ￿  106 in nondepleted animals to 34  +  3.8  ￿  106 after 
CD8 §  T  cell depletion. To exclude the possibility that the 
anti-CD8 + antibodies injected in vivo only blocked CD8 + 
binding rather than depleting CD8 + T  cells, the cell popu- 
lations were double-stained with anti-CD3 and either anti- 
CD4  or anti-CD8.  In the CD8 +  depleted mice, all CD3 + 
cells were also CD4 +. 
Sensitization to OVA Increases Total Cell Number 
and CD8  + T  Cells in PBLN 
Mice were  sensitized to  OVA via the airways by ultra- 
sonic nebulization on  10  consecutive  days. To  investigate 
possible changes in total cell number and T  cell distribution 
at the site of local allergen challenge, we analyzed PBLN of 
nonsensitized and sensitized animals for the distribution of 
CD4 +  and  CD8 +  T-cells.  After completion  of sensitiza- 
tion,  the PBLN  increased in total cell number by fivefold 
(3.9  +  0.8  ￿  106 PBLN cells per mouse after sensitization 
vs.  0.82  ~  0.08  ￿  106  PBLN  cells  per  nonsensitized 
mouse, P  <0.001).  This enlargement of the PBLN was ac- 
companied by a relative increase in the CD8 + T-cell subset 
(Fig. 2) with a shift in the CD4/CD8  ratio from 5.4 -  0.3 
in nonsensitized mice to  3.96  +  0.7  in sensitized animals 
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Figure  2. 
T cell distribution of PBLN cells 
after sensitization to OVA 
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Sensitization to  OVA increases the frequency  of CD8 + T 
cells in the PBLN. BALB/c mice were sensitized to OVA on days 1-10. 
PBLN were harvested on day 12 and stained for CD4 § and CD8 § T cells. 
Compared  are nonsensitized (PBS arl, n =  20), sensitized nondepleted 
(OVA ctrl, n =  16) and sensitized CD8+-depleted  animals (CD8 dept, n = 
20). Expressed are the frequencies as a percent of total PBLN cells for the 
two T  cell subsets from four independent experiments *P <:0.05 com- 
pared to PBS ctrl *P <0.001 compared to OVA ctrl. 
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Figure 3.  CD8 + T cell depletion increases total and OVA-specific lgE 
production after sensitization to OVA.  Serum from nonsensitized (PBS 
ctrl, n =  20), sensitized, nondepleted  (OVA ctrl, n =  16) and sensitized, 
CD8 T  cell-depleted mice (CD8 depl, n =  20) were obtained 2 d after 
completion  of OVA sensitization. Total lgE (ng/ml) and OVA-specific 
lgE levels (ELISA units, EU/ml) were measured by ELISA and compared 
to standards. Expressed are the mean + SD from four independent exper- 
iments. *P <0.05 compared to PBS control, not significant compared to 
OVA control; ~: not significant compared to OVA control. 
(P <0.04). This shift was due to an increase in the CD8 + T 
cell subset from  12.1  +  1.5% to  16.0  +  2.3% after sensiti- 
zation,  paralleled  by  a  relative  decrease  in  CD4 +  T  cells 
from 66.5  +  2.5% to 62.0 +- 2.8% after sensitization. 
Depleted Cell Fractions Do Not Recover after Sensitization 
with Allergen 
To  exclude  the possibility that  the  CD8 +  T  cell subset 
depleted by thymectomy and antibody treatment recovers 
or  expands  during  the  sensitization period,  we  analyzed 
spleen  MNC  and  PBLN  cells  2  d  after  completion  of 
the sensitization protocol.  The frequency of CD8 + T  cells 
remained  less  than  1%  in  PBLN  cells  and  spleen  MNC 
(0.6%  +- 0.5 and 0.7  +  0.4, respectively) (Fig. 2). This in- 
dicates that the depletion protocol was  efficient in remov- 
ing the  specific  T  cell subset  during the  whole  period  of 
sensitization without recovery of the depleted cell fraction. 
Effect of CD8 +  T  Cell Depletion on  0  Vii  Sensitization 
Serum Anti-OVA  and Total IgE Levels.  To  analyze the 
effect of CD8  T  cell depletion before sensitization on IgE 
production,  we  measured  total  IgE  and  aUergen-specific 
IgE  in  the  sera  of sensitized,  nondepleted  and  sensitized, 
CD8  T  cell-depleted animals. Serum was obtained imme- 
diately before  determination of airway responsiveness, 2 d 
after  completion  of the  10-d  OVA-nebulization  period. 
Depletion of CD8 +  T  cells resulted in an increase in total 
IgE  production  (Fig.  3);  total  IgE  levels  increased  from 
26  -+ 4  ng/ml for nondepleted mice to 43  +  10 ng/ml af- 
ter  CD8 +  depletion.  Allergen-specific  IgE  levels  of de- 
pleted animals remained essentially at the levels of nonde- 
pleted,  sensitized animals (2650  -+  350 EU/ml  vs 2500  +- 
300  EU/ml  in sensitized, nondepleted mice).  Both  of the 
groups  developed  significantly elevated  OVA-specific  IgE 
levels compared  to nondepleted, nonsensitized mice  (<10 
EU/ml;  P  <0.01). This indicates that sensitization to OVA 
via the airways leads to the production of allergen-specific 
IgE and that the depletion of CD8 + T  cells before sensiti- 
zation does  not interfere with  the  production of allergen- 
specific or total IgE. 
Immediate Cutaneous Hypersensitivity.  After intmdem~al in- 
jection of OVA,  the  majority of OVA-sensitized, nonde- 
pleted  mice  developed  allergen-specific  immediate  wheal 
responses (Table 1). Depletion ofCD8 + T  cells did not af- 
Table  1.  Effect of CD8 T  Cell Depletion  on Immediate 
Cutaneous Reactivity  to OVA 
Positive Responders 
Numbers  % 
PBS ctrl  0/20  0 
OVA ctrl*  14/16  87 
CD8 + depl~  17/20  85 
CD8  + T cell depletion does not alter immediate cutaneous hypersensi- 
tivity to OVA. Skin reactivity to OVA of nonsensitized (PBS ctrl, n = 
20), sensitized, nondepleted (OVA ctrl, n =  t6) and sensitized, CD8 T 
cell-depleted (CD8 depl, n =  20) mice was examined 1 d after comple- 
tion of the sensitization protocol.  Testing was by intradermal  injection 
of OVA (500 ~g/ml in PBS). Expressed are the percentages and num- 
bers  of positive  responders  to  OVA from four independent experi- 
ments. 
* P <0.001 compared with PBS ctrl. 
~t p <0.001 compared with PBS ctrl. 
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the data for allergen-specific IgE production. 
Development of Airway Hyperresponsiveness  Is Inhibited after 
CD8 T  Cell Depletion.  To evaluate AR. after sensitization 
to  OVA  via  the  airways,  we  stimulated segments  of tra- 
cheas  of individual mice  and  compared  the  electrical fre- 
quencies leading to half-maximal contraction (ESs0). Non- 
sensitized mice had ES50  values of 4.0  +  0.2  Hz  (Fig.  4). 
OVA-sensitized, nondepleted mice had ESs0 values of 2.65 
+  0.28, indicating AHR.  In sensitized animals depleted of 
CD8 §  T  cells, the response to EFS was similar to non-sen- 
sitized animals with a mean ESs0 of 3.87  +  0.20 (P <0.001 
compared  to  OVA-sensitized,  nondepleted  mice;  Fig.  4). 
These  data indicate that the development of hyperrespon- 
siveness of tracheal smooth muscles to electrical field stimu- 
lation after sensitization to  OVA  was prevented by deple- 
tion  of CD8 §  T  cells before  sensitization.  This  implies a 
pivotal role for this T  cell subset in the induction or regula- 
tion of increased airway responsiveness that is unrelated to 
effects on IgE production. 
Transfer of Nonprimed CD8 + T  Cells into CD8+-depleted 
Mice Restores the Ability to Develop AHR 
To  exclude  a  role  for non-specific effects  of the  anti- 
CD8 antibody treatment and confirm the role of CD8 + T 
cells  in  the  development  of  AHR.,  we  transferred  107 
CD8  + T cells are necessary for the development 













Figure  4. 
PBS ctrl  OVA ctrl  CD8 depl  CD8 trl 
CD8 T cell depletion prevents the development ofAHR af- 
ter OVA sensitization. Nonsensitized (PBS ctrl, n =  20), sensitized, non- 
depleted (OVA ctrl, n =  16), sensitized, CD8 T cell depleted (CD8  + depl, 
n =  20) and CD8 + T cell-depleted recipients ofCD8 + T cells (CD8  § t~ 
n =  8) are compared. 2 d after completion of the sensitization protocol to 
OVA, trachea smooth  muscle segments were  prepared  as described in 
Material and Methods and exposed to increasing frequencies of electrical 
field stimulation. Expressed are the mean +  SE of ESs0 values (frequencies 
resulting in 50% maximal contraction) as a percent of normal, untreated 
control  mice  (ESs0 3.8  -- 0.2) for the different groups *P <0.01  com- 
pared  to nonsensitized mice; *P <0.01  compared  to sensitized, nonde- 
pleted mice; ~P <0.03 compared to sensitized, CD8 T cell-depleted  ani- 
mals. 
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CD8 + T  cells from spleens of naive mice intravenously into 
CD8 T  cell-depleted recipients on day 8  of the 10-d sensi- 
tization protocol. A  group of CD8 T-cell depleted animals 
received a  similar number of CD8-depleted  splenic MNC 
(<1% CD8 §  T  cells) from naive mice at the same time. 
CD8 + T  Cell Transfer.  We analyzed spleen MNC,  PLN, 
and PBLN on day 12 (2 d after completion of sensitization) 
and compared  CD8  T  cell-depleted animals with CD8  T 
cell recipients. Following transfer, CD8 +  T  cells were  de- 
tected  in  recipient  animals.  The  highest  percentage  of 
CD8 +  T  cells  was  found  in  the  PBLN;  9.6  +  0.7%  of 
PBLN cells after transfer were CD8 + T  cells, whereas only 
3.4  +  0.4%  PLN  and  3.2  ---  0.3%  spleen  MNC  were 
CD8 +  after  transfer  (Fig.  5).  In  contrast,  the  number  of 
CD8 +  T  cells remained at  0.95  -+  0.2%  of PBLN  in de- 
pleted  animals that  received  CD8-depleted  spleen MNC. 
Thus,  transfer  of CD8 +  T  cells  resulted  in  a  10-fold  in- 
crease in the proportion of CD8 +  T  cells in the  PBLN  of 
the depleted animals. This suggests some selective accumu- 
lation ofCD8 + T  cells in the PBLN,  the site of local chal- 
lenge with allergen, as observed in nondepleted, sensitized 
animals (Fig. 2). 
Airway Reactivity.  Transfer of CD8 + T  cells from naive 
donor mice into CD8  T  cell-depleted recipients on day 8 
fully restored the ability to develop AHR  when assayed on 
day 12. CD8 T  cell recipients had ES50 values of 2.2  +  0.3 
Hz. Depleted control animals receiving CD8 T  cell-depleted 
spleen MNC  had ESs0 values of 3.9  +  0.2  (Fig. 4).  These 
data  indicate  that  transfer  of CD8 +  T  cells  into  CD8  T 
cell-depleted animals restores the ability to develop AHR. 
CD8  + T cells in spleens, PLN and PBLN 
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Figure  5.  Passive  transfer of CD8 + T cells into CD8 + T cell-depleted 
recipients. Mice were depleted of CD8  + T cells before sensitization. 107 
CD8 + T cells from naive donor mice were transferred i.v. on day 8 of the 
10-d sensitization protocol  (CD8 t~, n =  8). CD8 T cell~tepleted  con- 
trols (CD8 deft, n =  8) received similar numbers ofCD8 T cell-depleted 
spleen MNC. FACS  |  staining of spleen MNC, PLN, and PBLN was per- 
formed on day 12. Expressed are the frequencies ofCD8 § T cells in spleen, 
PLN and PBLN  cells from  two  independent experiments.  *P <0.001 
compared  to  spleen, PLN and PBLN  of nondepleted,  sensitized mice 
(OVA ctrl, n = 8); *P <0.04 compared to spleen and PLN ofCD8 T cell- 
depleted recipients of CD8  + T  cells (CD8 t~; ~P <0.05 compared  to 
PBLN of nonsensitized animals (PBS ctrl, n -- 8). CD8  T  Cell Depletion Inhibits and CD8 + T  Cell Transfer 
Restores Eosinophil Infiltration  into the Lung Tissue 
To investigate the  histological changes that  accompany 
sensitization to  OVA,  formalin-fixed lungs  of sensitized 
mice were stained for eosinophils with vital new red. Sensi- 
tization to OVA via the airways was accompanied by sig- 
nificant eosinophilic infiltration into the lung parenchyma. 
In nonsensitized animals, an average of 0.3  +  0.1  eosino- 
phils/hpf was  detected.  After  sensitization to  OVA,  the 
number increased by 15-fold to 5.2  +  0.4 eosinophils/hpf 
(P <0.01) (Fig. 6). Depletion of CD8 + T  cells significantly 
reduced this eosinophilic infiltration to  1.7  -+  0.3 eosino- 
phils/hpf (P  <0.04  compared  to  nondepleted, sensitized 
mice). Following transfer ofCD8 + T  cells, eosinophil infil- 
tration into the lungs was observed with numbers increas- 
ing to 5.1  +  0.2 eosinophils/hpf. These data indicate that 
depletion of CD8 + T  cells is associated with reduced eosi- 
nophil infiltration of the lung tissues after airway sensitiza- 
tion to OVA, and that the transfer ofCD8 + T  cells restores 
this response. 
In  Vivo and In  Vitro  CD8  T  Cell Depletion Decreases 
and CD8 + T  Cell Transfer Restores IL-5 Production 
in PBLN  Cells 
To assess IL-5 production at the site of the local allergen 
challenge during sensitization to  OVA,  PBLN  cells were 
stimulated for  48  h  with PMA/ionornycin. In PBLN  of 
sensitized, nondepleted animals, a  sixfold increase in IL-5 
production compared to  nonsensitized mice was  detected 
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Figure 6.  Development  of AHR is accompanied  by eosinophil  infiltra- 
tion of lung tissue. Formalin-fixed  lungs were cut into 5-p,m-thick slices 
and stained for eosinophils  with vital new red. Eosinophlls  were counted 
using 40￿  magnification.  Compared are nonsensitized  (PBS ctrl, n =  8), 
sensitized, nondepleted (OVA  ctrl,  n  =  8),  sensitized, CD8  T  cell- 
depleted animals  (CD8 depl, n =  8) and sensitized, CD8 T cell--depleted 
recipients of 107 unprimed CD8 + T cells (CD8 t~ n = 8) from two inde- 
pendent experiments.  Expressed are the mean + SD of numbers of eosi- 
nophlls per hpf. *P <0.01 compared to nonsensitized  animals;  *P <0.04 
compared to nondepleted, sensitized  mice; ~P <0.04 compared to sensi- 
tized, CD8+-depleted  animals. 
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Figure 7.  CD8 T cell depletion reduces and passive transfer  ofCD8 + T 
cells restores IL-5 production in PBLN after OVA sensitization.  PBLN 
were harvested 2 d a~er completion of the OVA sensitization  protocol 
and stimulated  for 48 h in the presence of PMA (10 nM) and ionomycin 
(0.5 p,M). IL-5 concentrations  in cell-free supernates were measured by 
ELISA. Compared are PBLN from nonsensitized  (PBS ctrl, n = 8), sensi- 
tized, nondepleted (OVA ctrl, n = 8), sensitized,  CD8 T cell-depleted  an- 
imals (CD8 depl in vivo, n =  8), CD8-depleted PBLN fi-om sensitized 
nondepleted mice (CD8 depl in vitro, n =  8) and sensitized, CD8 T cell- 
depleted recipients  of 107 unprimed CD8  + T cells (CD8 t~ n = 8) from 
two independent experiments.  Expressed are the mean -+ SD concentra- 
tions of IL-5 (pg/ml). *P <0.01  compared to  nonsensitized animals; 
*P <0.03 compared to nondepleted,  sensitized  mice; ~P <0.03 compared 
to sensitized, CD8 T cell-depleted  animals. 
(255  +  25 ng/ml at~er sensitization versus 40 -+ 5 ng/ml in 
nonsensitized controls,  P  <0.03)  (Fig.  7).  This  indicates 
that airway sensitization is  accompanied by an augmenta- 
tion of in vitro IL-5 production by cells at the site of aller- 
gen challenge. CD8 + T  cell depletion before sensitization 
resulted in a significant decrease in the production of IL-5 
by an equivalent number of sensitized PBLN cells. In paral- 
lel experiments, in vitro CD8  T-cell depletion of PBLN 
cells from OVA sensitized mice prior to culture also signif- 
icantly reduced IL-5 production by an equivalent number 
of cells. After transfer of CD8 + T  cells into CD8-depleted 
recipients on day 8,  the  in vitro production of IL-5 from 
PBLN was restored to similar levels as observed in nonde- 
pteted, sensitized animals. 
To  determine  if sensitization to  OVA  leads  to  an  in- 
crease in circulating levels of IL-5, we measured IL-5 con- 
centrations in the serum of sensitized mice,  one day after 
completion of sensitization. Measurable amounts of IL-5 
were only detected in sensitized, nondepleted animals and 
in sensitized,  CD8-depleted  recipients of CD8 +  T  cells; 
IL-5 serum concentrations reached 5  +  2 ng/ml and 3.8 + 
2.5 ng/ml, respectively. No IL-5 was detected in the serum 
of nonsensitized animals or sensitized, CD8-depleted ani- 
mals. 
CD8 + T  Cells Are a Major Source of lL-5 
To determine ifCD8 + T  cells are a major source oflL-5 
production themselves or indirectly augment IL-5 produc- 
tion by another cell type, we assessed  cytokine production 
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Figure  8.  Distribution  of IL-5 +  and  IFN-y §  T  cells in  PBLN  and 
spleen. PBLN and spleen MNC from OVA-sensitized mice were stimu- 
lated (PDB 10 nM, ionomycin 0.5 p,M, 4 h) and stained for cytoplasmic 
protein using anti-IL-5 or anti-IFN-y antibodies and for T  cell surface 
markers with  anti-CD4 and anti-CD8  antibodies.  Total  numbers of T 
cells  stained for  IL-5  were  4.5  +  0.5%  in  PBLN  and 3.4  -  0.8%  in 
spleen, total numbers of T  cells stained for IFN-~/ were 3.8  -+  1.2% in 
PBLN and 5.8  •  2.2% in spleen. Expressed is the distribution ofCD8 + 
and CD4 + T  cell subsets producing IL-5 and IFN-3' in PBLN and spleen 
from two independent experiments (n =  16). 
at  the  single  cell  level.  PBLN  and  spleen  MNC  from 
OVA-sensitized  mice  were  prepared,  stimulated  and 
stained with anti-cytokine antibodies as described (43). The 
distribution  of different T  cell subsets that stained for the 
specific cytokines was assessed.  Among PBLN T  cells,  4.5 
--+  0.5%  stained positively for IL-5 and 3.8  +  1.2% were 
positive for IFN-~.  In spleen,  the  frequency of IL-5  +  T 
cells  was  lower  (3.4  +  0.8%)  and  that  of IFN-~/+  cells 
higher (7.8  +  2.2%) compared to PBLN.  The majority of 
IL-5 + T  cells in the PBLN was CD3+/CD8 +, whereas less 
than one third of T  cells that stained positive for IL-5 were 
CD4 + (Fig.  8). In the spleen, the majority ofCD8 + T  cells 
were positive for IFN-~/and not IL-5. These data indicate 
that CD8 § T  cells are a major source oflL-5 in the PBLN 
of OVA-sensitized mice. 
Discussion 
The role ofCD8 + T  cells in allergic sensitization is obvi- 
ously complex. In the present study, we have investigated 
this  issue  by analyzing the  consequences  of in vivo CD8 
T-cell  depletion  before  sensitization  on  IgE  production, 
development of immediate cutaneous reactivity and AHR 
in  a  mouse  model  of airway sensitization.  In  contrast  to 
other  approaches  (44-46),  we  chose  the  combination  of 
thymectomy and injection  of monoclonal anti-CD8  anti- 
body to  deplete  CD8 +  T  cells.  Analysis of the peripheral 
lymphoid tissues  showed a virtually complete depletion of 
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the CD8 + T  cell 9opulation after this treatment. Compared 
to studies using antibody injections alone (without thymec- 
tomy),  this  approach provides  a  more  extensive and  sus- 
tained depletion of the target T  cell population (47).  Even 
after  12  d  of treatment  and  a  10-d  sensitization  protocol 
with  daily allergen  challenges,  CD8 +  T  cells  did  not re- 
cover in the spleen  or the local draining lymph nodes  of 
the airways. To assess the consequences of CD8 depletion 
on allergic sensitization,  we used a mouse model of local 
airway sensitization in the absence of adjuvant (38,  40).  In 
this model, depletion of CD8 § T  cells before sensitization 
of BALB/c  mice to  OVA via the  airways resulted in  in- 
creased  total  and  anti-OVA  IgE levels  after sensitization. 
Predictably, in light of the allergen-specific IgE responses, 
sensitized,  CD8  T  cell-depleted  mice developed allergen 
specific immediate cutaneous responses. 
Despite elevated allergen-specific IgE levels, CD8 T  cell 
depletion  before  sensitization  with  OVA  via  the  airways 
prevented the development of AHR; responses of tracheal 
smooth muscle preparations to EFS  were similar to those 
observed in nonsensitized animals. These results identify a 
critical role for CD8 § T  cells in the development of altered 
AR,  a finding  that was confirmed in  cell transfer experi- 
ments.  Transfer of CD8 +  T  cells  from naive  donor mice 
into CD8 T  cell--depleted recipients fully restored the de- 
velopment of AHR after sensitization; transfer of a similar 
number of T  cells,  depleted of CD8 + T  cells,  failed to re- 
store the increases in AR.  These data establish an essential 
role for CD8 + T  cells in the development of AHR during 
sensitization in our model. 
Transfer ofunprimed CD8 + T  cells on day 8 of the sen- 
sitization protocol appeared to be the optimal timepoint for 
reconstitution  of the  airway response.  Transfer of cells  at 
earlier time points was less  effective (data not shown)  and 
appeared to correlate with a reduced number of CD8 + T 
cells in the lymphoid organs, perhaps due to residual levels 
of anti-CD8  antibodies  remaining from the  last injection 
on day -3. On the other hand, cells transferred after com- 
pletion of sensitization  (day 10)  were unable to affect the 
outcome of AR.  Interestingly, when  CD8 +  T  cells  were 
transferred on day 8,  the  highest  frequencies  of CD8 +  T 
cells were detected in the PBLN. This may indicate an en- 
hanced homing ability of the transferred CD8 + T  cells  to 
the site of local allergen challenge.  This is in concert with 
our findings of the increase in CD8 + T  cell numbers in the 
PBLN following sensitization through the airways. 
Initial  studies  by other investigators  and  ourselves  em- 
phasized a suppressive function for CD8 + T  cells,  associat- 
ing IFN-'y-producing CD8 § T  cells with the inhibition of 
IgE production, and consequent downregulation of allergic 
sensitization (48, 49).  Nevertheless, expansion of CD8 + T 
cells  has been  detected  in patients  with bronchial  asthma 
(28,  29) as well as in animal models of airway sensitization 
(30--32).  Holt et al. estabhshed a model they termed "inha- 
lative tolerance," in rats  (50)  and  in mice  (51).  R.epeated 
sensitization, beginning in the newborn period, resuked in 
a progressive decrease in the production of allergen-specific 
IgE. Allergen-reactive CD8 + T  cells were capable of sup- pressing  IgE production  and  adoptively transferred  toler- 
ance in naive animals exposed to subsequent allergen chal- 
lenge.  As  described  below,  a  comparison  to  our  data  is 
difficult because of the use of adjuvant for sensitization. Ke- 
meny et al. studied a rat-model of sensitization using ricin 
as  an  adjuvant  for  allergen-specific  IgE-production  (52, 
53).  They reported  a  suppressive  effect of early activated 
CD8 +  T  cells  on IgE production  that was transferable  to 
naive animals (54).  Interestingly, in vivo depletion of CD8 + 
T  cells before sensitization with ricin and allergen did not 
lead to the predicted enhancement in IgE production, but 
instead,  inhibited  the  development of IgE responses  (55). 
From these experiments, they concluded that two distinct 
populations or different functional stages of CD8 + spleen T 
cells may exist,  one which suppresses  IgE responses through 
the  production  of IFN-~/ and  the  other which  augments 
IgE responses by an unknown mechanism. 
As with the  development of IgE responses,  there  are  a 
number of conflicting findings concerning the function of 
CD8 + T  cells in the development of AHR. In a study on 
mice, depletion ofCD8 + T  cells failed to influence eosino- 
phil infiltration of the trachea (56).  In rat models of allergic 
sensitization, depletion of CD8 + T  cells enhanced late air- 
way responses  (57)  and AHR  was transferable  into  naive 
recipients only by sensitized CD4 +, but not CD8 + spleen 
T  cells  (58).  However, there  are  major differences in  the 
design of the studies that may explain the contrast with our 
results.  In  our  model,  sensitization  of "high-responder" 
BALB/c  mice via the  airways in  the  absence of adjuvant 
induced AHR and depletion of CD8 + T  cells before sensi- 
tization  prevented  AHR.  In  the  study  of  rats,  "low- 
responder"  SD  rats  that  normally do  not  generate  AHR 
were  sensitized  systemically in  the  presence  of adjuvant, 
and CD8 + T  cells were depleted only after completion of 
sensitization. This approach fails to account for the role of 
CD8 + T  cells during sensitization. In addition, the different 
route  for  sensitization  and  especially the  use  of adjuvant 
may also fimit the effect of CD8 T  cell depletion after sen- 
sitization. This is supported by a study investigating the ef- 
fects of CD8 T  cell depletion in which a change from sub- 
cutaneous to intraperitoneal sensitization or sensitization in 
the presence of adjuvant restored the formerly inhibited de- 
velopment of delayed type hypersensitivity in CD8 T  cell- 
depleted mice (59). 
Mechanistically, the contribution ofCD8 + T  cells in the 
development of AH1L requires delineation. Following sen- 
sitization to OVA, we observed peribronchial infiltration of 
eosinophils  in  the  lung  parenchyma  and  increased  IL-5 
production by PBLN cells from sensitized animals. Deple- 
tion  of CD8 +  T  cells  before  sensitization  not  only  pre- 
vented the  development of AHP,. but was associated with 
markedly reduced  eosinophil  numbers  and  a  decrease  in 
IL-5  production  by  the  PBLN  cells.  Similarly,  in  vitro 
CD8  T  cell depletion of OVA-sensitized PBLN  cells  be- 
fore culture significantly reduced IL-5 production. Transfer 
of CD8 + T  cells into the CD8 T  cell-depleted animals not 
only restored the development of altered AP, but also fully 
restored the eosinophil response and IL-5 production. This 
supports the central role of eosinophils in the development 
of AHP,. (60)  and of interleukin 5  (IL-5) as the major en- 
hancing  factor for the  activation and  function  of eosino- 
phils in humans (14) and animals (15). 
Our data identify a critical role for CD8 + T  cells in the 
production of IL-5 during  allergic  sensitization.  This role 
may be an indirect one, through regulation ofCD4 + T  cell 
cytokine production (61),  or may reflect the production of 
IL-5 from sensitized  CD8 +  T  cells  themselves.  Our  data 
examining  production  of IL-5  directly  at  the  single  cell 
level demonstrated that in sensitized PBLN, CD8 § T  cells 
are the major source oflL-5 production. The differences in 
the cytokine profile of T  cells  in spleen and PBLN imply 
that the local environment during sensitization plays a ma- 
jor regulatory role in dictating the phenotype or functional 
development of CD8 + T  cells. CD8 + T  cells developing in 
the PBLN of animals sensitized via the airways are exposed 
to IL-4 produced by CD4 + T  cells in this environment and 
develop a TH2-fike phenotype.  In an environment where 
IFN-"/-production is  higher,  these  lymphocytes may de- 
velop into  cells  with a THl-like phenotype. Our demon- 
stration of the effects of IFN-~/ treatment support the im- 
portance  of the  local  environmental  influences:  systemic 
injection  of IFN-~/ only reduced total IgE levels, without 
affecting antigen-specific IgE production in mice sensitized 
exclusively through the airways. Only local administration 
of IFN-~/via the  airways was effective in inhibiting aller- 
gen-specific IgE production and preventing AHI< (62). 
The ability ofCD8 + T  cells to produce IL-4 and IL-5 in 
even larger amounts than CD4 +  T  cells  has  already been 
demonstrated  in  human  T  cell clones  and  recently in  rat 
splenic CD8 + T  cells (37,  reviewed in reference 63).  There 
now  is  increasing  evidence  for  the  presence  of TH2-1ike 
CD8 +  T  cells  in  humans,  rats  and  mice  (64-67).  When 
stimulated with IL-4, CD8 + T  cells increase IL-4 and IL-5 
production and lose the ability to produce IFN-y (37,  68, 
69). In transgenic mice expressing a virus-specific ix[~ T  cell 
receptor, challenge with the specific peptide after sensitiza- 
tion to a different antigen induced a Tri2-type immune re- 
sponse  that  triggered  CD8 +  T  cells  to  produce  high 
amounts  of IL-5,  resulting  in  eosinophil  accumulation  in 
the airways (70).  In our model, allergic sensitization of the 
airways triggers a T/q2-response leading to IL-4 production 
and  OVA-specific  IgE  production  in  this  environment 
(71).  It is in this environment that we propose the CD8 + T 
cells  become  committed  to  IL-5  production,  leading  to 
eosinophil  infiltration,  activation  and  altered  airway  re- 
sponsiveness. 
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